Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.35 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5885151 | 1.00 | LAP3 (0.35) | LAP3ALOX5SLC15A1HTTEPHX1 | |
| SCHEMBL6342303 | 1.00 | LAP3 (0.35) | LAP3ALOX5SLC15A1HTTEPHX1 | |
| SCHEMBL3131488 | 0.81 | HPGD (0.38) | ALOX5SLC15A1EPHX1HPGD | |
| SCHEMBL8411597 | 0.81 | FAAH (0.41) | LAP3FAAHABCB1HPGDTSHR | |
| SCHEMBL6342050 | 0.80 | ALOX5 (0.36) | LAP3ALOX5SLC15A1EPHX1 | |
| SCHEMBL6164405 | 0.78 | LAP3 (0.36) | LAP3ALOX5L3MBTL1 | |
| SCHEMBL8411083 | 0.77 | MMP9 (0.43) | HPGD | |
| SCHEMBL6354283 | 0.76 | UBE2N (0.36) | HPGDTSHR | |
| SCHEMBL28026869 | 0.75 | EPHX1 (0.46) | SLC15A1EPHX1L3MBTL1SRR | |
| SCHEMBL27660866 | 0.75 | EPHX1 (0.46) | SLC15A1EPHX1L3MBTL1SRR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867184-B2 | Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors | PFIZER, INC. (US) | 2005-03-15 | — | — | US | claimed |
| US-20040006088-A1 | For therapy of diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PFIZER INC. | 2004-01-08 | — | — | US | claimed |
| US-20020028810-A1 | Use in treating diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | HOOVER DENNIS J (US) | 2002-03-07 | — | — | US | claimed |
| US-20010053778-A1 | Pharmaceutical compositions of glycogen phosphorylase inhibitors | BEND RESEARCH, INC. | 2001-12-20 | — | — | US | claimed |
| US-20010046958-A1 | Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors | TREADWAY JUDITH L (US) | 2001-11-29 | — | — | US | claimed |
| US-6297269-B1 | Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors | PFIZER INC. | 2001-10-02 | — | — | US | claimed |
| EP-0832066-B1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER (US) | 2001-09-12 | — | — | EP | claimed |
| EP-1125580-A2 | Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-08-22 | — | — | EP | claimed |
| EP-1061074-A1 | Novel process and intermediates | Pfizer Products Inc. (US) | 2000-12-20 | — | — | EP | claimed |
| EP-0846464-A2 | Use of glycogen phosphorylase inhibitor for reducing non-cardiac tissue damage resulting from ischemia | PFIZER INC. (US) | 1998-06-10 | — | — | EP | claimed |
| EP-0832066-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1996039385-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1996-12-12 | — | — | WO | claimed |
| US-20150050371-A1 | Extract Formulations of Rhodamnia Cinerea And Uses Thereof | BIOTROPICS MALAYSIA BERHAD (MY) | 2015-02-19 | — | — | US | disclosed |
| WO-2013133685-A1 | EXTRACT FORMULATIONS OF RHODAMNIA CINEREA AND USES THEREOF | BIOTROPICS MALAYSIA BERHAD (MY) | 2013-09-12 | — | — | WO | disclosed |
| EP-1157695-B1 | Method of treating obesity using a neurotensin receptor ligand | PFIZER PROD INC (US) | 2006-06-28 | — | — | EP | disclosed |
| US-6974813-B2 | N-[(substituted five-membered di-or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia | WARNER-LAMBERT COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| WO-1999043663-A1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL] GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | PFIZER PRODUCTS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| EP-0846464-A2 | Use of glycogen phosphorylase inhibitor for reducing non-cardiac tissue damage resulting from ischemia | PFIZER INC. (US) | 1998-06-10 | — | — | EP | disclosed |
| EP-0832066-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996039385-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028810-A1 | Use in treating diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PYGL, GPR119, PYGM | LAP3 1486/4885ALOX5 1345/4885SLC15A1 1786/4885 |
| US-20040006088-A1 | For therapy of diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PYGL, GPR119, PYGM | LAP3 1545/4885ALOX5 1540/4885SLC15A1 1885/4885 |
| US-20010046958-A1 | Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors | PYGM, GYS1, PYGL | LAP3 913/4885ALOX5 2489/4885SLC15A1 2620/4885 |
| US-20010053778-A1 | Pharmaceutical compositions of glycogen phosphorylase inhibitors | PYGL, PYGM, GYS2 | LAP3 1381/4885ALOX5 3830/4885SLC15A1 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.